The NIH requires a data and safety monitoring board (DSMB) for Phase III clinical investigations (or any multi-site clinical trial) involving interventions that entail potential risk to participants. For phase I and II trials, a DSMB may be appropriate if the studies have multiple clinical sites, are blinded, or employ particularly high-risk interventions or vulnerable populations. The NCRR requires a DSMB for any investigation that places participants at significant risk.
Documents Available from NIH Agencies
[table id=25 /]
